BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 31184605)

  • 1. [Mutational Profiling of Pediatric Myeloid Leukemia Subtypes without Clinically Significant Chromosomal Aberrations].
    Ghukasyan LG; Krasnov GS; Muravenko OV; Baidun LV; Ibragimova SZ; Nasedkina TV
    Mol Biol (Mosk); 2019; 53(3):402-410. PubMed ID: 31184605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
    He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Genetic aberrations and new treatment strategies for pediatric acute myeloid leukemia].
    Shiba N
    Rinsho Ketsueki; 2018; 59(10):2260-2267. PubMed ID: 30305534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutational profiling of acute myeloid leukemia with normal cytogenetics in Brazilian patients: the value of next-generation sequencing for genomic classification.
    de Noronha TR; Mitne-Neto M; Chauffaille ML
    J Investig Med; 2017 Dec; 65(8):1155-1158. PubMed ID: 28923882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic classification of acute myeloid leukemia (AML).
    Haferlach T; Schnittger S; Kern W; Hiddemann W; Schoch C
    Ann Hematol; 2004; 83 Suppl 1():S97-100. PubMed ID: 15124693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing.
    Wang B; Liu Y; Hou G; Wang L; Lv N; Xu Y; Xu Y; Wang X; Xuan Z; Jing Y; Li H; Jin X; Deng A; Wang L; Gao X; Dou L; Liang J; Chen C; Li Y; Yu L
    Oncotarget; 2016 May; 7(22):32065-78. PubMed ID: 27062340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexisting and cooperating mutations in NPM1-mutated acute myeloid leukemia.
    Patel JL; Schumacher JA; Frizzell K; Sorrells S; Shen W; Clayton A; Jattani R; Kelley TW
    Leuk Res; 2017 May; 56():7-12. PubMed ID: 28152414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of patients with cytogenetically normal acute myeloid leukemia who have neither favorable nor unfavorable markers.
    Walker AR; Marcucci G
    J Natl Compr Canc Netw; 2014 Apr; 12(4):527-34. PubMed ID: 24717571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.
    Zhu YM; Wang PP; Huang JY; Chen YS; Chen B; Dai YJ; Yan H; Hu Y; Cheng WY; Ma TT; Chen SJ; Shen Y
    J Transl Med; 2017 Aug; 15(1):178. PubMed ID: 28830460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
    Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
    Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.
    Struski S; Lagarde S; Bories P; Puiseux C; Prade N; Cuccuini W; Pages MP; Bidet A; Gervais C; Lafage-Pochitaloff M; Roche-Lestienne C; Barin C; Penther D; Nadal N; Radford-Weiss I; Collonge-Rame MA; Gaillard B; Mugneret F; Lefebvre C; Bart-Delabesse E; Petit A; Leverger G; Broccardo C; Luquet I; Pasquet M; Delabesse E
    Leukemia; 2017 Mar; 31(3):565-572. PubMed ID: 27694926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic, immunophenotypic, and NPM1/FLT3 mutational studies on 17 patients with normal karyotype acute myeloid leukemia (AML) followed by aberrant karyotype AML at relapse.
    Wang ES; Sait SN; Gold D; Mashtare T; Starostik P; Ford LA; Wetzler M; Nowak NJ; Deeb G
    Cancer Genet Cytogenet; 2010 Oct; 202(2):101-7. PubMed ID: 20875872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of chromosomal aberrations in clonal diversity and progression of acute myeloid leukemia.
    Bochtler T; Fröhling S; Krämer A
    Leukemia; 2015 Jun; 29(6):1243-52. PubMed ID: 25673237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Radmacher MD; Mrózek K; Vukosavljevic T; Paschka P; Whitman SP; Langer C; Baldus CD; Liu CG; Ruppert AS; Powell BL; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2008 Nov; 26(31):5078-87. PubMed ID: 18809607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Driver Mutations in Acute Myeloid Leukemia with Inversion of Chromosome 16].
    Ghukasyan LG; Krasnov GS; Muravenko OV; Ikonnikova AY; Yurasov RA; Baidun LV; Ibragimova SZ; Nasedkina TV
    Mol Biol (Mosk); 2020; 54(3):389-397. PubMed ID: 32492002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia.
    Baldus CD; Bullinger L
    Semin Oncol; 2008 Aug; 35(4):356-64. PubMed ID: 18692686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current diagnosis and treatment for pediatric acute myeloid leukemia].
    Shiba N
    Rinsho Ketsueki; 2017; 58(4):389-399. PubMed ID: 28484171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.
    Schlenk RF; Döhner K; Krauter J; Fröhling S; Corbacioglu A; Bullinger L; Habdank M; Späth D; Morgan M; Benner A; Schlegelberger B; Heil G; Ganser A; Döhner H;
    N Engl J Med; 2008 May; 358(18):1909-18. PubMed ID: 18450602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.
    Balgobind BV; Van den Heuvel-Eibrink MM; De Menezes RX; Reinhardt D; Hollink IH; Arentsen-Peters ST; van Wering ER; Kaspers GJ; Cloos J; de Bont ES; Cayuela JM; Baruchel A; Meyer C; Marschalek R; Trka J; Stary J; Beverloo HB; Pieters R; Zwaan CM; den Boer ML
    Haematologica; 2011 Feb; 96(2):221-30. PubMed ID: 20971820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [AML treatment strategy based on cytogenetic abnormalities and somatic mutations].
    Imai Y
    Rinsho Ketsueki; 2015 Oct; 56(10):1932-41. PubMed ID: 26458431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.